Rare
lephants
Screener
Beta
Buy Me a Coffee
Toggle theme
PUMA BIOTECHNOLOGY, INC.
PBYI
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2021
FY2020
FY2019
Total Cash from Operations:
$49.0M
Line Item
Value
% of Total
Capital Expenditures
$71.0K
0.1%
Other Investing
$18.5M
37.8%
Other Financing
$23.2M
47.4%
Working Capital
$7.2M
14.7%
Net Cash Flow
$0
0.0%